Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Eledon Pharmaceuticals, Inc. (ELDN)
USD4.00
-0.06 (-1.36%)
US NASDAQ Healthcare Biotechnology
Address
19900 MacArthur Boulevard 92612
Irvine, CA, US
Irvine, CA, US
CEO
David-Alexandre C. Gros
Website
eledon.com
IPO
2014-09-17
CIK 1404281 ISIN US28617K1016
Description
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.00
-0.06 (-1.36%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.96
Float Shares
54.44M
Free Float %
90.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.09% | +2.63% | +25.81% | +94.03% | +106.35% | +158.28% | +35.89% | +61.83% | -58.06% | -99.63% | -99.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
4.00
Low
5.00
+25.2%
Consensus
5.00
+25.2%
Median
5.00
+25.2%
High
5.00
+25.2%
DCF (Unlevered)
0.24
-94.1%
DCF (Levered)
0.27
-93.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
5.00
+25.2%
|
| Last Year | 2 |
7.00
+75.2%
|
| All Time | 2 |
7.00
+75.2%
|
Quality scores
Altman Z-Score
-1.60
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+25.3% Q1'26: -22,712.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-2,038.5% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+68.6% Q1'26: +45.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 50.00M (-100.0%)
|
—
— – —
-100.0% YoY
|
—
— – —
|
17.40M
17.40M – 17.40M
|
21.94M
21.94M – 21.94M
+26.1% YoY
|
7.13M
7.13M – 7.13M
-67.5% YoY
|
| EBITDA |
-35.39M
|
-83.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-35.75M
|
-83.25M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-36.18M
est: -33.85M (-6.9%)
|
-45.62M
est: -57.07M (+20.1%)
|
-71.69M
-84.61M – -58.77M
-25.6% YoY
|
-69.97M
-69.97M – -69.97M
+2.4% YoY
|
-73.24M
-83.47M – -63.01M
-4.7% YoY
|
-61.65M
-61.65M – -61.65M
+15.8% YoY
|
-56.88M
-56.88M – -56.88M
+7.7% YoY
|
| SGA |
18.25M
|
16.98M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-0.75
est: -0.70 (-6.9%)
|
-0.56
est: -0.67 (+16.8%)
|
-0.88
-1.03 – -0.72
-30.1% YoY
|
-0.86
-0.86 – -0.86
+2.4% YoY
|
-0.90
-1.02 – -0.77
-5.7% YoY
|
-0.75
-0.75 – -0.75
+16.6% YoY
|
-0.70
-0.70 – -0.70
+7.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-103.44M
OE per share TTM
0.75
Owner's Yield
-35.16%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,726.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
35
Total invested
6.10M
Insider transactions (90d)
1
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 3.57M | 6.10% | — | 3.57M | — | 3.57M | HC, IN | Delaware | 2024-11-05 | ↗ |
| 2 | RA Capital Healthcare Fund, L.P. | 3.57M | 6.10% | — | 3.57M | — | 3.57M | PN | Delaware | 2024-11-05 | ↗ |
| 3 | RA Capital Management, L.P. | 3.57M | 6.10% | — | 3.57M | — | 3.57M | IA, PN | Delaware | 2024-11-05 | ↗ |
| 4 | Rajeev Shah | 3.57M | 6.10% | — | 3.57M | — | 3.57M | HC, IN | Delaware | 2024-11-05 | ↗ |
| 5 | James N. Topper | 3.56M | 6.10% | — | 3.56M | — | 3.56M | IN | Delaware | 2024-11-05 | ↗ |
| 6 | Patrick J. Heron | 3.56M | 6.10% | — | 3.56M | — | 3.56M | IN | Delaware | 2024-11-05 | ↗ |
| 7 | Albert Cha | 3.44M | 5.90% | — | 3.44M | — | 3.44M | IN | Delaware | 2024-11-05 | ↗ |
| 8 | James Brush | 3.44M | 5.90% | — | 3.44M | — | 3.44M | IN | Delaware | 2024-11-05 | ↗ |
| 9 | FHMLSP, L.L.C. | 2.66M | 4.60% | — | 2.66M | — | 2.66M | OO | Delaware | 2024-11-05 | ↗ |
| 10 | FHMLSP, L.P. | 2.66M | 4.60% | — | 2.66M | — | 2.66M | PN | Delaware | 2024-11-05 | ↗ |
| 11 | Frazier Life Sciences Public Fund, L.P. | 2.66M | 4.60% | — | 2.66M | — | 2.66M | PN | Delaware | 2024-11-05 | ↗ |
| 12 | Armistice Capital, LLC | 2.44M | 9.99% | — | 2.44M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 13 | Steven Boyd | 2.44M | 9.99% | — | 2.44M | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
| 14 | Bihua Chen | 1.43M | 9.90% | — | 1.43M | — | 1.43M | IN | Cayman Islands | 2022-02-14 | ↗ |
| 15 | Cormorant Asset Management, LP | 1.43M | 9.90% | — | 1.43M | — | 1.43M | PN | Cayman Islands | 2022-02-14 | ↗ |
| 16 | Cormorant Global Healthcare GP, LLC | 1.43M | 9.90% | — | 1.43M | — | 1.43M | OO | Cayman Islands | 2022-02-14 | ↗ |
| 17 | Cormorant Global Healthcare Master Fund, LP | 1.43M | 9.90% | — | 1.43M | — | 1.43M | PN | Cayman Islands | 2022-02-14 | ↗ |
| 18 | FHMLSP Overage, L.L.C. | 783.9K | 1.40% | — | 783.9K | — | 783.9K | OO | Delaware | 2024-11-05 | ↗ |
| 19 | FHMLSP Overage, L.P. | 783.9K | 1.40% | — | 783.9K | — | 783.9K | PN | Delaware | 2024-11-05 | ↗ |
| 20 | Frazier Life Sciences Public Overage Fund, L.P. | 783.9K | 1.40% | — | 783.9K | — | 783.9K | PN | Delaware | 2024-11-05 | ↗ |
| 21 | Daniel Estes | 80.5K | 0.10% | — | 80.5K | — | 80.5K | IN | Delaware | 2024-11-05 | ↗ |
| 22 | FHMLS XI, L.L.C. | 80.5K | 0.10% | — | 80.5K | — | 80.5K | OO | Delaware | 2024-11-05 | ↗ |
| 23 | FHMLS XI, L.P. | 80.5K | 0.10% | — | 80.5K | — | 80.5K | PN | Delaware | 2024-11-05 | ↗ |
| 24 | Frazier Life Sciences XI, L.P. | 80.5K | 0.10% | — | 80.5K | — | 80.5K | PN | Delaware | 2024-11-05 | ↗ |
| 25 | FHMLS X, L.L.C. | 39.5K | 0.10% | — | 39.5K | — | 39.5K | OO | Delaware | 2024-11-05 | ↗ |
| 26 | FHMLS X, L.P. | 39.5K | 0.10% | — | 39.5K | — | 39.5K | PN | Delaware | 2024-11-05 | ↗ |
| 27 | Frazier Life Sciences X, L.P. | 39.5K | 0.10% | — | 39.5K | — | 39.5K | PN | Delaware | 2024-11-05 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
35
-62 vs prev Q
New positions
18
Closed positions
78
Increased
24
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 70.2K +70.2K (+100.0%) | 105.95M +106.0M (+100.0%) | 0.09% +0.091 pp | 0.08% +0.082 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 2 | BVF INC/IL | 6.29M +— (+0.0%) | 9.50M -6.8M (-41.7%) | 8.16% +0.000 pp | 0.32% -0.341 pp | USD3.96 -61.9% | 20 qtrs — |
| 3 | VANGUARD GROUP INC | 4.04M +771.9K (+23.6%) | 6.10M -2.4M (-27.9%) | 5.24% +1.000 pp | 0.00% +0.000 pp | USD3.66 -58.7% | 20 qtrs — |
| 4 | BLACKROCK, INC. | 3.63M +162.1K (+4.7%) | 5.48M -3.5M (-39.0%) | 4.70% +0.210 pp | 0.00% 0.000 pp | USD2.80 -46.1% | 6 qtrs — |
| 5 | ENSIGN PEAK ADVISORS, INC | 2.46M +1.2M (+94.9%) | 3.72M +445.9K (+13.6%) | 3.19% +1.555 pp | 0.01% +0.001 pp | USD2.62 -42.4% | 21 qtrs — |
| 6 | ZIMMER PARTNERS, LP | 2.38M +559.2K (+30.6%) | 3.60M -1.1M (-23.8%) | 3.09% +0.725 pp | 0.09% -0.007 pp | USD2.32 -34.9% | 7 qtrs — |
| 7 | SPHERA FUNDS MANAGEMENT LTD. | 2.13M +851.9K (+66.5%) | 3.22M -96.3K (-2.9%) | 2.76% +1.104 pp | 0.62% -0.077 pp | USD2.59 -41.7% | 7 qtrs — |
| 8 | BLUE OWL CAPITAL HOLDINGS LP | 1.93M +950.0K (+96.9%) | 2.91M +376.2K (+14.8%) | 2.50% +1.231 pp | 0.22% -0.570 pp | USD2.84 -46.8% | 5 qtrs — |
| 9 | ADAR1 CAPITAL MANAGEMENT, LLC | 1.82M +1.8M (+100.0%) | 2.75M +2.8M (+100.0%) | 2.36% +2.361 pp | 0.20% +0.202 pp | USD1.51 +0.0% | 5 qtrs — |
| 10 | JEFFERIES FINANCIAL GROUP INC. | 1.58M +1.6M (+100.0%) | 2.39M +2.4M (+100.0%) | 2.05% +2.049 pp | 0.01% +0.012 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.42M +52.7K (+3.8%) | 2.15M -1.4M (-39.5%) | 1.84% +0.068 pp | 0.00% 0.000 pp | USD3.52 -57.1% | 20 qtrs — |
| 12 | CATALIO CAPITAL MANAGEMENT, LP | 1.26M +198.7K (+18.7%) | 1.90M -846.0K (-30.8%) | 1.63% +0.258 pp | 0.34% -0.172 pp | USD2.42 -37.6% | 2 qtrs — |
| 13 | AWM INVESTMENT COMPANY, INC. | 1.10M +1.1M (+100.0%) | 1.66M +1.7M (+100.0%) | 1.43% +1.426 pp | 0.16% +0.160 pp | USD1.51 +0.0% | 5 qtrs — |
| 14 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 1.04M +1.0M (+100.0%) | 1.57M +1.6M (+100.0%) | 1.35% +1.347 pp | 0.19% +0.187 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 15 | STONEPINE CAPITAL MANAGEMENT, LLC | 893.1K +893.1K (+100.0%) | 1.35M +1.3M (+100.0%) | 1.16% +1.158 pp | 0.98% +0.985 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 16 | SANOFI | 815.0K +— (+0.0%) | 1.23M -880.2K (-41.7%) | 1.06% +0.000 pp | 0.40% -0.414 pp | USD4.12 -63.3% | 5 qtrs — |
| 17 | STATE STREET CORP | 773.9K +118.4K (+18.1%) | 1.17M -529.1K (-31.2%) | 1.00% +0.154 pp | 0.00% +0.000 pp | USD2.82 -46.5% | 19 qtrs — |
| 18 | CM MANAGEMENT, LLC | 650.0K +50.0K (+8.3%) | 981.5K -572.5K (-36.8%) | 0.84% +0.065 pp | 0.83% -0.468 pp | USD3.22 -53.1% | 20 qtrs — |
| 19 | 22NW, LP | 636.4K +— (+0.0%) | 960.9K -687.3K (-41.7%) | 0.82% +0.000 pp | 0.40% -0.372 pp | USD3.39 -55.5% | 4 qtrs — |
| 20 | SG AMERICAS SECURITIES, LLC | 627.4K +627.4K (+100.0%) | 947.0K +947.0K (+100.0%) | 0.81% +0.813 pp | 0.00% +0.001 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 21 | UBS GROUP AG | 593.1K +499.7K (+534.7%) | 895.6K +653.6K (+270.0%) | 0.77% +0.648 pp | 0.00% +0.000 pp | USD1.74 -13.2% | 17 qtrs — |
| 22 | CALIGAN PARTNERS LP | 556.0K +556.0K (+100.0%) | 839.5K +839.5K (+100.0%) | 0.72% +0.721 pp | 0.07% +0.069 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 23 | JANE STREET GROUP, LLC | 489.4K +294.2K (+150.7%) | 739.0K +233.4K (+46.2%) | 0.63% +0.381 pp | 0.00% +0.000 pp | USD1.94 -22.2% | 5 qtrs — |
| 24 | NORTHERN TRUST CORP | 429.8K +1.3K (+0.3%) | 649.0K -461.0K (-41.5%) | 0.56% +0.002 pp | 0.00% 0.000 pp | USD3.12 -51.6% | 20 qtrs — |
| 25 | COLONY GROUP, LLC | 317.4K +317.4K (+100.0%) | 479.3K +479.3K (+100.0%) | 0.41% +0.411 pp | 0.00% +0.001 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 26 | MORGAN STANLEY | 240.5K +1.4K (+0.6%) | 363.2K -256.2K (-41.4%) | 0.31% +0.002 pp | 0.00% +0.000 pp | USD3.11 -51.4% | 20 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 198.7K +137.7K (+225.7%) | 300.1K +142.1K (+89.9%) | 0.26% +0.179 pp | 0.00% +0.000 pp | USD2.01 -24.9% | 5 qtrs — |
| 28 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 195.8K +195.8K (+100.0%) | 285.8K +285.8K (+100.0%) | 0.25% +0.254 pp | 0.00% +0.003 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 29 | RENAISSANCE TECHNOLOGIES LLC | 177.0K -172.2K (-49.3%) | 267.3K -637.2K (-70.5%) | 0.23% -0.223 pp | 0.00% -0.001 pp | USD2.71 -44.3% | 20 qtrs — |
| 30 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 173.1K +10.3K (+6.3%) | 261.4K -160.3K (-38.0%) | 0.22% +0.013 pp | 0.00% +0.000 pp | USD2.72 -44.5% | 12 qtrs — |
| 31 | BOOTHBAY FUND MANAGEMENT, LLC | 151.6K +151.6K (+100.0%) | 228.9K +228.9K (+100.0%) | 0.20% +0.196 pp | 0.00% +0.003 pp | USD1.51 +0.0% | 5 qtrs — |
| 32 | BANK OF NEW YORK MELLON CORP | 132.9K -13.0K (-8.9%) | 200.7K -177.1K (-46.9%) | 0.17% -0.017 pp | 0.00% +0.000 pp | USD2.70 -44.1% | 3 qtrs — |
| 33 | XTX TOPCO LTD | 124.2K +111.4K (+867.1%) | 187.6K +154.3K (+463.8%) | 0.16% +0.144 pp | 0.00% +0.003 pp | USD1.62 -6.8% | 2 qtrs — |
| 34 | DIMENSIONAL FUND ADVISORS LP | 115.7K -19.1K (-14.2%) | 174.7K -174.0K (-49.9%) | 0.15% -0.025 pp | 0.00% +0.000 pp | USD3.14 -51.9% | 7 qtrs — |
| 35 | QUADRATURE CAPITAL LTD | 106.0K +78.9K (+291.2%) | 160.1K +89.8K (+127.6%) | 0.14% +0.102 pp | 0.00% +0.001 pp | USD1.82 -17.0% | 3 qtrs — |
| 36 | BARCLAYS PLC | 87.5K +7.7K (+9.7%) | 132.1K -74.5K (-36.1%) | 0.11% +0.010 pp | 0.00% +0.000 pp | USD3.49 -56.7% | 5 qtrs — |
| 37 | NUVEEN, LLC | 76.3K +— (+0.0%) | 115.2K -82.4K (-41.7%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 38 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 71.7K +35.0K (+95.5%) | 108.2K +13.3K (+14.0%) | 0.09% +0.045 pp | 0.00% +0.000 pp | USD2.06 -26.7% | 2 qtrs — |
| 39 | GRAHAM CAPITAL MANAGEMENT, L.P. | 70.3K +70.3K (+100.0%) | 106.1K +106.1K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.003 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 40 | WELLS FARGO & COMPANY/MN | 68.9K +20.4K (+41.9%) | 104.0K -21.7K (-17.3%) | 0.09% +0.026 pp | 0.00% +0.000 pp | USD2.34 -35.5% | 3 qtrs — |
| 41 | AQR CAPITAL MANAGEMENT LLC | 60.2K +60.2K (+100.0%) | 90.9K +90.9K (+100.0%) | 0.08% +0.078 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 42 | BANK OF AMERICA CORP /DE/ | 60.1K +14.9K (+32.9%) | 90.7K -26.4K (-22.5%) | 0.08% +0.019 pp | 0.00% +0.000 pp | USD2.52 -40.1% | 9 qtrs — |
| 43 | KERA CAPITAL PARTNERS, INC. | 39.8K +14.0K (+54.3%) | 87.5K +20.8K (+31.1%) | 0.05% +0.018 pp | 0.01% +0.001 pp | USD3.20 -52.8% | 5 qtrs — |
| 44 | INGALLS & SNYDER LLC | 51.8K +— (+0.0%) | 78.0K -56.0K (-41.8%) | 0.07% +0.000 pp | 0.00% -0.002 pp | USD10.52 -85.6% | 20 qtrs — |
| 45 | CITADEL ADVISORS LLC | 49.8K +49.8K (+100.0%) | 75.2K +75.2K (+100.0%) | 0.06% +0.065 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 46 | RHUMBLINE ADVISERS | 44.6K -8.9K (-16.7%) | 67.4K -71.4K (-51.4%) | 0.06% -0.012 pp | 0.00% 0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 47 | INVESCO LTD. | 31.7K -222.0 (-0.7%) | 47.8K -34.8K (-42.1%) | 0.04% 0.000 pp | 0.00% +0.000 pp | USD2.70 -44.1% | 3 qtrs — |
| 48 | MARCO INVESTMENT MANAGEMENT LLC | 30.3K +— (+0.0%) | 45.8K -32.8K (-41.7%) | 0.04% +0.000 pp | 0.00% -0.003 pp | USD2.08 -27.4% | 8 qtrs — |
| 49 | HOWARD FINANCIAL SERVICES, LTD. | 30.0K +— (+0.0%) | 45.3K -32.4K (-41.7%) | 0.04% +0.000 pp | 0.01% -0.004 pp | USD2.71 -44.3% | 3 qtrs — |
| 50 | PRICE T ROWE ASSOCIATES INC /MD/ | 29.5K +— (+0.0%) | 45.0K -32.0K (-41.6%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 51 | MARSHALL WACE, LLP | 29.5K +29.5K (+100.0%) | 44.6K +44.6K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 5 qtrs — |
| 52 | CANADA PENSION PLAN INVESTMENT BOARD | 29.4K +29.4K (+100.0%) | 44.4K +44.4K (+100.0%) | 0.04% +0.038 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 53 | TOWER RESEARCH CAPITAL LLC (TRC) | 27.4K +16.7K (+156.4%) | 41.3K +13.7K (+49.5%) | 0.04% +0.022 pp | 0.00% +0.000 pp | USD1.93 -21.8% | 19 qtrs — |
| 54 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 26.8K -1.9K (-6.6%) | 40.5K -33.9K (-45.6%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD3.48 -56.6% | 11 qtrs — |
| 55 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 26.8K -828.0 (-3.0%) | 40.4K -31.0K (-43.4%) | 0.03% -0.001 pp | 0.00% 0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 56 | CETERA INVESTMENT ADVISERS | 26.6K +11.2K (+72.9%) | 40.1K +316.0 (+0.8%) | 0.03% +0.015 pp | 0.00% +0.000 pp | USD2.13 -29.1% | 2 qtrs — |
| 57 | VIRTU FINANCIAL LLC | 25.9K +25.9K (+100.0%) | 39.0K +39.0K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.002 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 58 | MILLENNIUM MANAGEMENT LLC | 23.8K +23.8K (+100.0%) | 35.9K +35.9K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 5 qtrs — |
| 59 | INTECH INVESTMENT MANAGEMENT LLC | 22.9K -3.1K (-11.8%) | 34.5K -32.6K (-48.6%) | 0.03% -0.004 pp | 0.00% 0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 60 | JPMORGAN CHASE & CO | 22.4K -249.0 (-1.1%) | 33.9K -24.9K (-42.3%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 61 | TWO SIGMA SECURITIES, LLC | 19.3K +19.3K (+100.0%) | 29.2K +29.2K (+100.0%) | 0.03% +0.025 pp | 0.00% +0.004 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 62 | TIAA TRUST, NATIONAL ASSOCIATION | 19.0K +19.0K (+100.0%) | 28.7K +28.7K (+100.0%) | 0.02% +0.025 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 63 | MERCER GLOBAL ADVISORS INC /ADV | 17.7K +881.0 (+5.2%) | 26.7K -16.8K (-38.6%) | 0.02% +0.001 pp | 0.00% +0.000 pp | USD5.93 -74.5% | 18 qtrs — |
| 64 | LPL FINANCIAL LLC | 17.5K +3.8K (+27.9%) | 26.4K -9.0K (-25.4%) | 0.02% +0.005 pp | 0.00% +0.000 pp | USD2.35 -35.7% | 2 qtrs — |
| 65 | MARINER, LLC | 12.4K +12.4K (+100.0%) | 18.7K +18.7K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 66 | BNP PARIBAS ARBITRAGE, SNC | 11.9K -271.0 (-2.2%) | 17.9K -13.5K (-43.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD2.64 -42.8% | 3 qtrs — |
| 67 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 11.9K -9.4K (-44.3%) | 17.9K -37.2K (-67.5%) | 0.02% -0.012 pp | 0.00% 0.000 pp | USD2.67 -43.4% | 3 qtrs — |
| 68 | SUMMIT FINANCIAL, LLC | 11.5K +— (+0.0%) | 17.4K -12.4K (-41.7%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD2.59 -41.7% | 2 qtrs — |
| 69 | VOYA INVESTMENT MANAGEMENT LLC | 11.4K +— (+0.0%) | 17.2K -12.3K (-41.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 70 | RUSSELL INVESTMENTS GROUP, LTD. | 10.8K +5.9K (+122.1%) | 16.3K +3.7K (+29.5%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD2.00 -24.5% | 2 qtrs — |
| 71 | RAYMOND JAMES FINANCIAL INC | 10.6K +10.6K (+100.0%) | 16.0K +16.0K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 3 qtrs — |
| 72 | PROSHARE ADVISORS LLC | 10.3K +10.3K (+100.0%) | 15.5K +15.5K (+100.0%) | 0.01% +0.013 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 3 qtrs — |
| 73 | FORUM PRIVATE CLIENT GROUP LLC | 10.0K +10.0K (+100.0%) | 15.1K +15.1K (+100.0%) | 0.01% +0.013 pp | 0.01% +0.005 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 74 | AMERITAS INVESTMENT PARTNERS, INC. | 6.0K +— (+0.0%) | 9.0K -6.5K (-41.7%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 75 | LEGAL & GENERAL GROUP PLC | 5.3K +— (+0.0%) | 8.1K -5.8K (-41.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 76 | FMR LLC | 4.7K +4.4K (+1,812.7%) | 7.1K +6.4K (+1,014.3%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD1.57 -3.8% | 8 qtrs — |
| 77 | NEW YORK STATE COMMON RETIREMENT FUND | 4.2K +— (+0.0%) | 6.3K -4.5K (-41.7%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 78 | STERLING CAPITAL MANAGEMENT LLC | 3.7K +15.0 (+0.4%) | 5.5K -3.9K (-41.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.63 -42.6% | 3 qtrs — |
| 79 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 3.5K -205.0 (-5.6%) | 5.2K -4.3K (-45.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 80 | CWM, LLC | 2.0K +2.0K (+100.0%) | 3.0K +3.0K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 81 | AMALGAMATED BANK | 1.8K -237.0 (-11.8%) | 3.0K -2.0K (-40.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 82 | ROYAL BANK OF CANADA | 1.6K -36.3K (-95.8%) | 3.0K -95.0K (-96.9%) | 0.00% -0.047 pp | 0.00% +0.000 pp | USD2.71 -44.3% | 3 qtrs — |
| 83 | ADDISON ADVISORS LLC | 1.3K +— (+0.0%) | 2.0K -1.4K (-41.7%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD4.12 -63.3% | 5 qtrs — |
| 84 | CITIGROUP INC | 1.3K +469.0 (+57.9%) | 1.9K -168.0 (-8.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD3.16 -52.2% | 5 qtrs — |
| 85 | CLEARSTEAD ADVISORS, LLC | 500.00 +500.0 (+100.0%) | 755.00 +755.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 86 | ADVISOR GROUP HOLDINGS, INC. | 405.00 -9.6K (-96.0%) | 611.00 -25.3K (-97.6%) | 0.00% -0.012 pp | 0.00% +0.000 pp | USD2.59 -41.7% | 2 qtrs — |
| 87 | EVERSOURCE WEALTH ADVISORS, LLC | 349.00 +349.0 (+100.0%) | 527.00 +527.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.51 +0.0% | 1 qtrs NEW |
| 88 | SBI SECURITIES CO., LTD. | 63.00 -48.0 (-43.2%) | 95.00 -192.0 (-66.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.73 -44.7% | 5 qtrs — |
| 89 | ROTHSCHILD INVESTMENT LLC | 24.00 +24.0 (+100.0%) | 36.00 +36.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.50 +0.7% | 1 qtrs NEW |
| 90 | PNC FINANCIAL SERVICES GROUP, INC. | 5.00 -4.0 (-44.4%) | 8.00 -15.0 (-65.2%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.40 -37.1% | 2 qtrs — |
| 91 | BYRNE ASSET MANAGEMENT LLC | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +51.0% | 1 qtrs NEW |
| 92 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | — -19.1K (-100.0%) | — -49.4K (-100.0%) | 0.00% -0.025 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 93 | WELLINGTON MANAGEMENT GROUP LLP | — -1.3M (-100.0%) | — -3.3M (-100.0%) | 0.00% -1.664 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 94 | VELAN CAPITAL INVESTMENT MANAGEMENT LP | — -347.0K (-100.0%) | — -898.7K (-100.0%) | 0.00% -0.450 pp | 0.00% -0.844 pp | USD— | 5 qtrs SOLD |
| 95 | KOVITZ INVESTMENT GROUP PARTNERS, LLC | — -733.0K (-100.0%) | — -1.9M (-100.0%) | 0.00% -0.950 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 46 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.07% | 982.6K | 0.60% |
| 2 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 272.1K | 0.20% |
| 3 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.02% | 68.6K | 0.39% |
| 4 | iShares Russell 2000 Growth ETF IWO | 0.02% | 2.79M | 0.24% |
| 5 | Vanguard Russell 2000 Value ETF VTWV | 0.02% | 208.0K | 0.06% |
| 6 | State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc) R2US.L | 0.01% | 645.2K | 0.30% |
| 7 | iShares Russell 2000 BuyWrite ETF IWMW | 0.01% | 5.5K | 0.39% |
| 8 | iShares Russell 2000 ETF IWM | 0.01% | 8.00M | 0.19% |
| 9 | iShares U.S. Small Cap Index ETF (CAD-Hedged) XSU.TO | 0.01% | 52.2K | 0.36% |
| 10 | Xtrackers Russell 2000 UCITS ETF 1C XRSU.L | 0.01% | 271.4K | 0.30% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
1.00
Neutral
Buys
6
Sells
6
Shares acquired
25.7K
Shares disposed
25.7K
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2035-01-10 | Robinson James A. Jr. | Director | A-Award | A | Stock Option (right to buy) | 30,870 | 4.04 | 124.7K | 30,870 | D | ↗ |
| 2026-01-10 | Robinson James A. Jr. | Director | M-Exempt | D | Restricted Stock Units | 3,430 | 0.00 | — | 0 | D | ↗ |
| 2026-01-10 | McBride John S. | Director | M-Exempt | A | Common Stock | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2026-01-10 | Lee June | Director | M-Exempt | D | Restricted Stock Units | 3,430 | 0.00 | — | 0 | D | ↗ |
| 2026-01-10 | Kirk Allan | Director | M-Exempt | D | Restricted Stock Units | 3,430 | 0.00 | — | 0 | D | ↗ |
| 2026-01-10 | Katkin Keith | Director | M-Exempt | A | Common Stock | 8,575 | 0.00 | — | 8,575 | D | ↗ |
| 2026-01-10 | Hillson Jan | Director | M-Exempt | D | Restricted Stock Units | 3,430 | 0.00 | — | 0 | D | ↗ |
| 2025-01-10 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 150,500 | 4.04 | 608.0K | 150,500 | D | ↗ |
| 2025-01-10 | Robinson James A. Jr. | Director | A-Award | A | Restricted Stock Units | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2025-01-10 | Perrin Steven | Director / Officer | A-Award | A | Restricted Stock Units | 27,000 | 0.00 | — | 27,000 | D | ↗ |
| 2025-01-10 | McBride John S. | Director | A-Award | A | Restricted Stock Units | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2025-01-10 | Little Paul Sean | Officer | A-Award | A | Restricted Stock Units | 75,000 | 0.00 | — | 75,000 | D | ↗ |
| 2025-01-10 | Lee June | Director | A-Award | A | Restricted Stock Units | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2025-01-10 | Kirk Allan | Director | A-Award | A | Restricted Stock Units | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2025-01-10 | Katkin Keith | Director | A-Award | A | Restricted Stock Units | 8,575 | 0.00 | — | 8,575 | D | ↗ |
| 2025-01-10 | Hillson Jan | Director | A-Award | A | Restricted Stock Units | 3,430 | 0.00 | — | 3,430 | D | ↗ |
| 2025-01-10 | Gros David-Alexandre C | Director / Officer | A-Award | A | Restricted Stock Units | 66,500 | 0.00 | — | 66,500 | D | ↗ |
| 2024-11-21 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 474,350 | 2.30 | 1.09M | 474,350 | D | ↗ |
| 2024-11-21 | Perrin Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 840,438 | 2.30 | 1.93M | 840,438 | D | ↗ |
| 2024-11-21 | Little Paul Sean | Officer | A-Award | A | Stock Option (right to buy) | 525,032 | 2.30 | 1.21M | 525,032 | D | ↗ |
| 2024-11-21 | Gros David-Alexandre C | Director / Officer | A-Award | A | Stock Option (right to buy) | 1,015,743 | 2.30 | 2.34M | 1,015,743 | D | ↗ |
| 2024-10-29 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Pre-funded Warrants to Purchase Common Stock | 2,213,816 | 0.00 | 2.2K | 7,415,596 | D | ↗ |
| 2024-06-13 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 241,650 | 2.30 | 555.8K | 241,650 | — | ↗ |
| 2024-06-13 | Perrin Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 428,148 | 2.30 | 984.7K | 428,148 | — | ↗ |
| 2024-06-13 | Little Paul Sean | Officer | A-Award | A | Stock Option (right to buy) | 267,470 | 2.30 | 615.2K | 267,470 | — | ↗ |
| 2024-06-13 | Gros David-Alexandre C | Director / Officer | A-Award | A | Stock Option (right to buy) | 517,454 | 2.30 | 1.19M | 517,454 | — | ↗ |
| 2024-05-09 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Common Stock, $0.001 par value | 1,031,385 | 2.37 | 2.44M | 3,361,803 | — | ↗ |
| 2023-10-02 | Robinson James A. Jr. | Director | A-Award | A | Stock Option (Right to Buy) | 150,437 | 1.55 | 233.2K | 150,437 | — | ↗ |
| 2023-10-02 | Kirk Allan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-01 | Robinson James A. Jr. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-05 | BVF PARTNERS L P/IL | 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 3,084,090 | 3.00 | 9.25M | 3,084,090 | — | ↗ |
| 2023-05-01 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 179,000 | 2.30 | 411.7K | 179,000 | — | ↗ |
| 2023-05-01 | Perrin Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 317,147 | 2.30 | 729.4K | 317,147 | — | ↗ |
| 2023-05-01 | Ogier Walter C | Director | A-Award | A | Stock Option (right to buy) | 150,437 | 2.30 | 346.0K | 150,437 | — | ↗ |
| 2023-05-01 | McBride John S. | Director | A-Award | A | Stock Option (right to buy) | 150,437 | 2.30 | 346.0K | 150,437 | — | ↗ |
| 2023-05-01 | Little Paul Sean | Officer | A-Award | A | Stock Option (right to buy) | 198,126 | 2.30 | 455.7K | 198,126 | — | ↗ |
| 2023-05-01 | Lee June | Director | A-Award | A | Stock Option (right to buy) | 150,437 | 2.30 | 346.0K | 150,437 | — | ↗ |
| 2023-05-01 | LYONS GARY A | Director | A-Award | A | Common Stock | 150,437 | 2.30 | 346.0K | 150,437 | — | ↗ |
| 2023-05-01 | Katkin Keith | Director | A-Award | A | Stock Option (right to buy) | 752,185 | 2.30 | 1.73M | 752,185 | — | ↗ |
| 2023-05-01 | Hillson Jan | Director | A-Award | A | Stock Option (right to buy) | 150,437 | 2.30 | 346.0K | 150,437 | — | ↗ |
| 2023-05-01 | Gros David-Alexandre C | Director / Officer | A-Award | A | Common Stock (right to buy) | 383,299 | 2.30 | 881.6K | 383,299 | — | ↗ |
| 2023-02-01 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 3.08 | 477.4K | 155,000 | — | ↗ |
| 2023-02-01 | Perrin Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 3.08 | 477.4K | 155,000 | — | ↗ |
| 2023-02-01 | Ogier Walter C | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | McBride John S. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | Little Paul Sean | Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 3.08 | 477.4K | 155,000 | — | ↗ |
| 2023-02-01 | Lee June | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | LYONS GARY A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | Katkin Keith | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | Hillson Jan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.08 | 61.6K | 20,000 | — | ↗ |
| 2023-02-01 | Gros David-Alexandre C | Director / Officer | A-Award | A | Stock Option (right to buy) | 153,600 | 3.97 | 609.8K | 153,600 | — | ↗ |
| 2022-11-23 | Perrin Steven | Officer | P-Purchase | A | Common Stock | 1,000 | 2.60 | 2.6K | 1,000 | — | ↗ |
| 2022-02-01 | Smith Bryan E. | Officer | A-Award | A | Stock Option (right to buy) | 120,000 | 3.97 | 476.4K | 120,000 | — | ↗ |
| 2022-02-01 | Perrin Steven | Director / Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 3.97 | 615.4K | 155,000 | — | ↗ |
| 2022-02-01 | Ogier Walter C | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | McBride John S. | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | Little Paul Sean | Officer | A-Award | A | Stock Option (right to buy) | 155,000 | 3.97 | 615.4K | 155,000 | — | ↗ |
| 2022-02-01 | Lee June | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | LYONS GARY A | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | Katkin Keith | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | Hillson Jan | Director | A-Award | A | Stock Option (right to buy) | 20,000 | 3.97 | 79.4K | 20,000 | — | ↗ |
| 2022-02-01 | Gros David-Alexandre C | Director / Officer | A-Award | A | Stock Option (right to buy) | 108,000 | 3.97 | 428.8K | 108,000 | — | ↗ |
| 2022-01-20 | BVF PARTNERS L P/IL | 10% Owner | — | D | Warrants to Purchase Common Stock | 11,415 | 12.96 | 147.9K | 0 | — | ↗ |
| 2021-12-20 | Gros David-Alexandre C | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 4.48 | 9.0K | 9,000 | — | ↗ |
| 2021-08-17 | Gros David-Alexandre C | Director / Officer | P-Purchase | A | Common Stock | 4,000 | 6.21 | 24.8K | 7,000 | — | ↗ |
| 2021-07-01 | Hillson Jan | Director | — | D | Stock Option (Right to Buy) | 40,000 | 7.68 | 307.2K | 0 | — | ↗ |
| 2021-06-11 | Little Paul Sean | Officer | P-Purchase | A | Common Stock | 10,000 | 8.87 | 88.7K | 10,000 | — | ↗ |
| 2021-06-09 | Gros David-Alexandre C | Director / Officer | P-Purchase | A | Common Stock | 3,000 | 8.01 | 24.0K | 3,000 | — | ↗ |
| 2021-05-03 | Smith Bryan E. | Officer | A-Award | A | Stock Option (Right to Buy) | 158,500 | 9.91 | 1.57M | 158,500 | — | ↗ |
| 2021-04-19 | Smith Bryan E. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-15 | Little Paul Sean | Officer | — | D | Stock Option (Right to Buy) | 160,000 | 13.94 | 2.23M | 0 | — | ↗ |
| 2020-12-22 | BVF PARTNERS L P/IL | — | C-Conversion | D | Series X1 Convertible Preferred Stock | 11,776 | 0.00 | — | 52,145 | — | ↗ |
| 2020-12-08 | Lee June | Director | — | D | Stock Option (Right to Buy) | 40,000 | 19.74 | 789.6K | 0 | — | ↗ |
| 2020-12-02 | OrbiMed Israel GP Ltd. | 10% Owner | S-Sale | D | Common Stock | 103,200 | 21.60 | 2.23M | 73,650 | — | ↗ |
| 2020-10-30 | Logos Global Management LP | 10% Owner | P-Purchase | A | Common Stock | 4,000 | 25.97 | 103.9K | 185,000 | — | ↗ |
| 2020-10-01 | BVF PARTNERS L P/IL | 10% Owner | — | D | Series X1 Convertible Preferred Stock | 473,038 | 0.00 | — | 0 | — | ↗ |
| 2020-09-14 | Perrin Steven | Director / Officer | — | D | Stock Option (Right to Buy) | 14,802 | 0.50 | 7.3K | 0 | — | ↗ |
| 2020-09-14 | Ogier Walter C | Director | — | D | Stock Option (Right to Buy) | 462 | 685.50 | 316.5K | 0 | — | ↗ |
| 2020-09-11 | McBride John S. | Director | A-Award | A | Stock Option (Right to Buy) | 1,167 | 500.00 | 583.6K | 1,167 | — | ↗ |
| 2020-09-11 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 1,167 | 500.00 | 583.6K | 1,167 | — | ↗ |
| 2020-09-11 | Kuwahara Jon | Officer | A-Award | A | Stock Option (Right to Buy) | 2,145 | 500.00 | 1.07M | 2,145 | — | ↗ |
| 2020-09-11 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 5,907 | 500.00 | 2.95M | 5,907 | — | ↗ |
| 2020-09-11 | Gros David-Alexandre C | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 18,278 | 500.00 | 9.14M | 18,278 | — | ↗ |
| 2020-09-09 | Gros David-Alexandre C | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-03-19 | TURKEL CATHERINE C. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.26 | 26.0K | 100,000 | — | ↗ |
| 2020-03-19 | Kuwahara Jon | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 0.26 | 13.0K | 50,000 | — | ↗ |
| 2020-03-19 | FLESHER GREGORY J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 0.26 | 52.0K | 200,000 | — | ↗ |
| 2020-01-14 | OrbiMed Israel GP Ltd. | Director / 10% Owner | S-Sale | A | Warrants to Purchase Common Stock | 646,204 | 0.00 | — | 0 | — | ↗ |
| 2020-01-14 | Chimovits Erez | Director / 10% Owner | S-Sale | A | Warrants to Purchase Common Stock | 646,204 | 0.00 | — | 0 | — | ↗ |
| 2019-09-26 | TURKEL CATHERINE C. | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 0.67 | 50.3K | 75,000 | — | ↗ |
| 2019-09-26 | Kuwahara Jon | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 0.67 | 40.2K | 60,000 | — | ↗ |
| 2019-09-26 | FLESHER GREGORY J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.67 | 67.0K | 100,000 | — | ↗ |
| 2019-07-11 | McBride John S. | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.88 | 17.6K | 20,000 | — | ↗ |
| 2019-07-11 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.88 | 17.6K | 20,000 | — | ↗ |
| 2019-07-11 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.88 | 17.6K | 20,000 | — | ↗ |
| 2019-07-11 | Cohen Cheryl | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.88 | 17.6K | 20,000 | — | ↗ |
| 2019-07-11 | Chimovits Erez | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.88 | 17.6K | 20,000 | — | ↗ |
| 2019-05-21 | TURKEL CATHERINE C. | Officer | S-Sale | D | Common Stock | 1,914 | 1.91 | 3.7K | 88,662 | — | ↗ |
| 2019-05-21 | Kuwahara Jon | Officer | S-Sale | D | Common Stock | 1,058 | 1.91 | 2.0K | 5,974 | — | ↗ |
| 2019-05-21 | FLESHER GREGORY J. | Director / Officer | S-Sale | D | Common Stock | 2,937 | 1.91 | 5.6K | 156,918 | — | ↗ |
| 2019-05-20 | TURKEL CATHERINE C. | Officer | S-Sale | D | Common Stock | 7,623 | 1.96 | 15.0K | 90,576 | — | ↗ |
| 2019-05-20 | Kuwahara Jon | Officer | S-Sale | D | Common Stock | 4,218 | 1.96 | 8.3K | 7,032 | — | ↗ |
| 2019-05-20 | FLESHER GREGORY J. | Director / Officer | S-Sale | D | Common Stock | 11,701 | 1.96 | 23.0K | 159,855 | — | ↗ |
| 2019-05-02 | OrbiMed Israel GP Ltd. | Director / 10% Owner | P-Purchase | A | Warrants to Purchase Common Stock | 646,204 | 0.00 | — | 646,204 | — | ↗ |
| 2019-05-02 | Chimovits Erez | Director | P-Purchase | A | Common Stock | 646,204 | 3.10 | 2.00M | 3,183,314 | — | ↗ |
| 2019-04-30 | LIFESCI INDEX PARTNERS LLC | 10% Owner | S-Sale | D | Common Stock, par value $0.01 per share | 200 | 2.70 | 540.00 | 1,065,867 | — | ↗ |
| 2019-03-14 | TURKEL CATHERINE C. | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 98,199 | — | ↗ |
| 2019-03-14 | Kuwahara Jon | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 3.72 | 93.0K | 25,000 | — | ↗ |
| 2019-03-14 | FLESHER GREGORY J. | Director / Officer | A-Award | A | Common Stock | 25,000 | 0.00 | — | 171,556 | — | ↗ |
| 2018-09-12 | TURKEL CATHERINE C. | Officer | P-Purchase | A | Common Stock | 16,632 | 5.02 | 83.5K | 78,199 | — | ↗ |
| 2018-09-11 | TURKEL CATHERINE C. | Officer | P-Purchase | A | Common Stock | 17,048 | 4.56 | 77.7K | 61,567 | — | ↗ |
| 2018-09-05 | TURKEL CATHERINE C. | Officer | P-Purchase | A | Common Stock | 805 | 3.97 | 3.2K | 805 | — | ↗ |
| 2018-06-13 | McBride John S. | Director | A-Award | A | Stock Option (Right to Buy) | 9,100 | 6.18 | 56.2K | 9,100 | — | ↗ |
| 2018-06-13 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 9,100 | 6.18 | 56.2K | 9,100 | — | ↗ |
| 2018-06-13 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 9,100 | 6.18 | 56.2K | 9,100 | — | ↗ |
| 2018-06-13 | Cohen Cheryl | Director | A-Award | A | Stock Option (Right to Buy) | 9,100 | 6.18 | 56.2K | 9,100 | — | ↗ |
| 2018-03-13 | TURKEL CATHERINE C. | Officer | A-Award | A | Common Stock | 20,000 | 0.00 | — | 44,519 | — | ↗ |
| 2018-03-13 | Kuwahara Jon | Officer | A-Award | A | Stock Option (Right to Buy) | 12,000 | 4.83 | 58.0K | 12,000 | — | ↗ |
| 2018-03-13 | FLESHER GREGORY J. | Director / Officer | A-Award | A | Common Stock | 30,700 | 0.00 | — | 146,556 | — | ↗ |
| 2018-03-09 | LIFESCI INDEX PARTNERS LLC | 10% Owner | — | I | Common Stock, $.001 par value | 0 | 0.00 | — | 1,066,067 | — | ↗ |
| 2017-11-06 | TURKEL CATHERINE C. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.21 | 210.5K | 50,000 | — | ↗ |
| 2017-07-10 | Kuwahara Jon | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-30 | Morrison Jodie Pope | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 5.85 | 105.3K | 18,000 | — | ↗ |
| 2017-06-30 | McBride John S. | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 5.85 | 105.3K | 18,000 | — | ↗ |
| 2017-06-30 | LYONS GARY A | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 5.85 | 105.3K | 18,000 | — | ↗ |
| 2017-06-30 | Katkin Keith | Director | A-Award | A | Stock Option (Right to Buy) | 36,000 | 5.85 | 210.6K | 36,000 | — | ↗ |
| 2017-06-30 | Cohen Cheryl | Director | A-Award | A | Stock Option (Right to Buy) | 18,000 | 5.85 | 105.3K | 18,000 | — | ↗ |
| 2017-05-24 | TURKEL CATHERINE C. | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 5.50 | 288.8K | 52,500 | — | ↗ |
| 2017-05-24 | OCAMPO CHRISTINE | Officer | A-Award | A | Stock Option (Right to Buy) | 52,500 | 5.50 | 288.8K | 52,500 | — | ↗ |
| 2017-05-24 | FLESHER GREGORY J. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 5.50 | 1.38M | 250,000 | — | ↗ |
| 2017-05-10 | TURKEL CATHERINE C. | Officer | — | D | Stock Option (Right to Buy) | 1,073 | 19.76 | 21.2K | 0 | — | ↗ |
| 2017-05-10 | OCAMPO CHRISTINE | Officer | — | D | Stock Option (Right to Buy) | 1,341 | 19.76 | 26.5K | 0 | — | ↗ |
| 2017-05-10 | LYONS GARY A | Director | — | D | No Securities Owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-05-10 | Katkin Keith | Director | — | D | Stock Option (Right to Buy) | 5,363 | 19.76 | 106.0K | 0 | — | ↗ |
| 2017-05-10 | FLESHER GREGORY J. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 56,897 | — | ↗ |
| 2017-05-10 | Chimovits Erez | Director | — | I | Common Stock | 0 | 0.00 | — | 2,537,110 | — | ↗ |
| 2017-05-09 | OrbiMed Israel GP Ltd. | Director / 10% Owner | A-Award | A | Common Stock | 2,537,110 | 0.00 | — | 2,537,110 | — | ↗ |
| 2016-06-16 | Cohen Cheryl | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-06-15 | Yanchik Joseph A., III | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-06-15 | Kessler David A. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-06-15 | Harrison Seth Loring | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-06-15 | Buckley Stephen Jr. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-06-15 | BARBERICH TIMOTHY J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 6.29 | 75.5K | 12,000 | — | ↗ |
| 2016-03-15 | Buckley Stephen Jr. | Director | P-Purchase | A | Common Stock | 8,000 | 5.74 | 45.9K | 11,000 | — | ↗ |
| 2016-01-08 | Morrison Jodie Pope | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 20,000 | 1.37 | 27.4K | 37,878 | — | ↗ |
| 2015-12-15 | Quirk Gerald E | Officer | A-Award | A | Stock Option (right to buy) | 62,000 | 9.65 | 598.3K | 62,000 | — | ↗ |
| 2015-12-15 | Morrison Jodie Pope | Director / Officer | A-Award | A | Stock Option (right to buy) | 189,000 | 9.65 | 1.82M | 189,000 | — | ↗ |
| 2015-12-15 | McBride John S. | Officer | A-Award | A | Stock Option (right to buy) | 62,000 | 9.65 | 598.3K | 62,000 | — | ↗ |
| 2015-12-15 | Kalowski Lee | Officer | A-Award | A | Stock Option (right to buy) | 62,000 | 9.65 | 598.3K | 62,000 | — | ↗ |
| 2015-12-15 | Ferrante Karen Jean | Officer | A-Award | A | Stock Option (right to buy) | 62,000 | 9.65 | 598.3K | 62,000 | — | ↗ |
| 2015-11-11 | Buckley Stephen Jr. | Director | P-Purchase | A | Common Stock | 3,000 | 11.25 | 33.8K | 3,000 | — | ↗ |
| 2015-09-21 | McBride John S. | Officer | M-Exempt | A | Common Stock | 13,500 | 4.19 | 56.6K | 13,500 | — | ↗ |
| 2015-09-08 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 4,668 | 13.13 | 61.3K | 40,953 | — | ↗ |
| 2015-09-02 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 2,158 | 12.96 | 28.0K | 45,621 | — | ↗ |
| 2015-07-29 | Morrison Jodie Pope | Director / Officer | M-Exempt | A | Common Stock | 3,000 | 1.37 | 4.1K | 29,551 | — | ↗ |
| 2015-07-28 | Morrison Jodie Pope | Director / Officer | M-Exempt | A | Common Stock | 12,000 | 1.58 | 19.0K | 31,551 | — | ↗ |
| 2015-07-22 | Morrison Jodie Pope | Director / Officer | M-Exempt | A | Common Stock | 7,426 | 0.63 | 4.7K | 19,551 | — | ↗ |
| 2015-07-15 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 3,566 | 14.26 | 50.8K | 4,493,458 | — | ↗ |
| 2015-07-14 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 27,861 | 14.41 | 401.5K | 4,497,024 | — | ↗ |
| 2015-07-13 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 20,611 | 14.20 | 292.7K | 4,524,885 | — | ↗ |
| 2015-06-29 | Morrison Jodie Pope | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 8,000 | 1.58 | 12.6K | 325,300 | — | ↗ |
| 2015-06-26 | Morrison Jodie Pope | Director / Officer | S-Sale | D | Common Stock | 8,000 | 13.83 | 110.6K | 9,551 | — | ↗ |
| 2015-06-24 | McBride John S. | Officer | S-Sale | D | Common Stock | 300 | 14.20 | 4.3K | 0 | — | ↗ |
| 2015-06-23 | McBride John S. | Officer | S-Sale | D | Common Stock | 6,700 | 14.00 | 93.8K | 0 | — | ↗ |
| 2015-06-22 | McBride John S. | Officer | S-Sale | D | Common Stock | 2,000 | 14.02 | 28.0K | 0 | — | ↗ |
| 2015-06-17 | Yanchik Joseph A., III | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 14.04 | 168.5K | 12,000 | — | ↗ |
| 2015-06-17 | Kessler David A. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 14.04 | 168.5K | 12,000 | — | ↗ |
| 2015-06-17 | Harrison Seth Loring | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 12,000 | 14.04 | 168.5K | 12,000 | — | ↗ |
| 2015-06-17 | Buckley Stephen Jr. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 14.04 | 168.5K | 12,000 | — | ↗ |
| 2015-06-17 | BARBERICH TIMOTHY J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 14.04 | 168.5K | 12,000 | — | ↗ |
| 2015-06-16 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 1,120 | 14.27 | 16.0K | 4,545,496 | — | ↗ |
| 2015-06-12 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 5,919 | 14.20 | 84.0K | 4,561,393 | — | ↗ |
| 2015-06-11 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 27,875 | 14.20 | 395.8K | 4,567,312 | — | ↗ |
| 2015-05-26 | Quirk Gerald E | Officer | A-Award | A | Stock Option (right to buy) | 214,605 | 10.81 | 2.32M | 214,605 | — | ↗ |
| 2015-04-16 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 4,567 | 13.00 | 59.4K | 47,779 | — | ↗ |
| 2015-04-09 | Cohen Cheryl | Director | — | D | No securities are beneficially owned | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-04-02 | Kalowski Lee | Officer | S-Sale | D | Common Stock | 2,258 | 11.45 | 25.9K | 52,346 | — | ↗ |
| 2015-03-19 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 46,141 | 14.50 | 669.0K | 4,595,187 | — | ↗ |
| 2015-03-18 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 3,000 | 14.50 | 43.5K | 4,641,328 | — | ↗ |
| 2015-01-08 | Buckley Stephen Jr. | Director | A-Award | A | Stock Option (right to buy) | 25,000 | 14.49 | 362.3K | 25,000 | — | ↗ |
| 2014-10-15 | Morrison Jodie Pope | Director / Officer | A-Award | A | Stock Option (right to buy) | 134,134 | 13.25 | 1.78M | 134,134 | — | ↗ |
| 2014-10-15 | McBride John S. | Officer | A-Award | A | Stock Option (right to buy) | 50,671 | 13.25 | 671.4K | 50,671 | — | ↗ |
| 2014-09-22 | Satter Muneer A | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 15.00 | 2.25M | 1,771,688 | — | ↗ |
| 2014-09-22 | Novartis Bioventures Ltd | 10% Owner | C-Conversion | D | Series D-3 Preferred Stock | 13,222,826 | 0.00 | — | 0 | — | ↗ |
| 2014-09-22 | Morrison Jodie Pope | Director / Officer | A-Award | A | Stock Option (right to buy) | 165,251 | 1.58 | 261.1K | 165,251 | — | ↗ |
| 2014-09-22 | Harrison Seth Loring | Director / 10% Owner | C-Conversion | D | Series D-1 Preferred Stock | 8,711,335 | 0.00 | — | 0 | — | ↗ |
| 2014-09-22 | BARBERICH TIMOTHY J | Director | C-Conversion | D | Series E Preferred Stock | 809,955 | 0.00 | — | 0 | — | ↗ |
| 2014-09-22 | Apple Tree Partners IV, L.P. | Director / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 125,000 | — | ↗ |
| 2014-09-22 | Apple Tree Partners II - Annex, L.P. | Director / 10% Owner | P-Purchase | A | Common Stock | 237,500 | 15.00 | 3.56M | 3,568,438 | — | ↗ |
| 2014-09-22 | APPLE TREE PARTNERS II LP | Director / 10% Owner | C-Conversion | D | Series A Preferred Stock | 4,500,000 | 0.00 | — | 0 | — | ↗ |
| 2014-09-17 | Kalowski Lee | Officer | A-Award | A | Stock Option (right to buy) | 218,417 | 15.00 | 3.28M | 218,417 | — | ↗ |
| 2014-09-16 | Yanchik Joseph A., III | Director | — | D | Stock Option (right to buy) | 21,658 | 0.63 | 13.6K | 0 | — | ↗ |
| 2014-09-16 | Williams Martin D | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 168,850 | — | ↗ |
| 2014-09-16 | Warman Investments Pty. Ltd. | 10% Owner | — | D | Series B-2 Preferred Stock | 5,469 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | Wade Denis Newell | 10% Owner | — | I | Series E Preferred Stock | 37,440 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | Thomas Robert Bain | 10% Owner | — | I | Series B-2 Preferred Stock | 5,469 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | Stewart Susan B. | 10% Owner | — | D | Stock Option (right to buy) | 14,326 | 0.63 | 9.0K | 0 | — | ↗ |
| 2014-09-16 | Satter Muneer A | 10% Owner | — | I | Series D-2 Preferred Stock | 43,716 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | QBF No. 2 Pty Ltd as trustee for Queensland BioCapital Fund No. 2 | 10% Owner | — | D | Series B-2 Preferred Stock | 27,348 | 0.00 | — | 0 | — | ↗ |
| 2014-09-16 | QBF No. 1 Pty Ltd as trustee for Queensland BioCapital Fund No. 1 | 10% Owner | — | D | Series B-2 Preferred Stock | 27,348 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
59.95M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 613.2K | — | 268.7K | 1.96M | 349.5K | 21.7K | 3.22M | 69.39% | ↗ |
| 2 | 2025 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 484.9K | — | 109.1K | 795.0K | 284.3K | 23.0K | 1.70M | 53.30% | ↗ |
| 3 | 2025 | Paul Little Chief Financial Officer | 479.2K | — | 303.0K | 572.6K | 215.2K | 23.0K | 1.59M | 54.97% | ↗ |
| 4 | 2024 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 582.3K | — | — | 4.58M | 464.3K | 21.4K | 5.64M | 81.08% | ↗ |
| 5 | 2024 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 455.3K | — | — | 3.79M | 306.9K | 22.0K | 4.57M | 82.85% | ↗ |
| 6 | 2024 | Paul Little Chief Financial Officer | 459.4K | — | — | 2.37M | 242.4K | 22.7K | 3.09M | 76.56% | ↗ |
| 7 | 2023 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 559.5K | — | — | 1.69M | 286.4K | 20.5K | 2.55M | 66.07% | ↗ |
| 8 | 2023 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 437.4K | — | — | 906.4K | 175.6K | 21.1K | 1.54M | 58.84% | ↗ |
| 9 | 2023 | Paul Little Chief Financial Officer | 441.4K | — | — | 699.1K | 159.5K | 21.1K | 1.32M | 52.92% | ↗ |
| 10 | 2022 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 532.5K | — | — | 310.5K | 256.7K | 18.8K | 1.12M | 27.76% | ↗ |
| 11 | 2022 | Paul Little Chief Financial Officer | 421.1K | — | — | 445.7K | 175.0K | 15.6K | 1.06M | 42.15% | ↗ |
| 12 | 2022 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 417.1K | — | — | 445.7K | 167.3K | 19.6K | 1.05M | 42.46% | ↗ |
| 13 | 2021 | Paul Little Chief Financial Officer | 323.3K | — | — | 1.85M | 131.2K | 2.3K | 2.31M | 80.21% | ↗ |
| 14 | 2021 | Bryan Smith General Counsel, Corporate Secretary and Compliance Officer | 276.9K | 100.0K | — | 1.31M | — | 213.00 | 1.68M | 77.59% | ↗ |
| 15 | 2021 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 503.7K | — | — | — | 242.4K | 1.5K | 747.5K | 0.00% | ↗ |
| 16 | 2021 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 402.9K | — | — | — | 161.6K | 2.3K | 566.8K | 0.00% | ↗ |
| 17 | 2020 | David-Alexandre C. Gros, M.D. Chief Executive Officer | 150.0K | — | — | 7.18M | — | 92.4K | 7.42M | 96.73% | ↗ |
| 18 | 2020 | Steven Perrin, Ph.D. President and Chief Scientific Officer | 122.3K | — | — | 2.99M | — | — | 3.11M | 96.07% | ↗ |
| 19 | 2020 | Gregory J. Flesher Former Chief Executive Officer | 364.5K | 121.7K | — | 611.8K | — | 1.32M | 2.42M | 25.33% | ↗ |
| 20 | 2020 | Jon S. Kuwahara Senior Vice President of Finance and Administration | 319.0K | 45.0K | — | 851.2K | — | 3.1K | 1.22M | 69.86% | ↗ |
| 21 | 2020 | Catherine C. Turkel Former President | 202.8K | 83.5K | — | 216.5K | — | 685.4K | 1.19M | 18.22% | ↗ |
| 22 | 2019 | Gregory J. Flesher Former Chief Executive Officer | 480.4K | — | 66.8K | 293.7K | — | 1.7K | 842.7K | 42.78% | ↗ |
| 23 | 2019 | Gregory J. Flesher Chief Executive Officer | 480.4K | — | 66.8K | 293.7K | — | 1.7K | 842.7K | 42.78% | ↗ |
| 24 | 2019 | Catherine C. Turkel Former President | 368.4K | — | 53.5K | 171.7K | — | 4.1K | 597.7K | 37.67% | ↗ |
| 25 | 2019 | Catherine C. Turkel President | 368.4K | — | 53.5K | 171.7K | — | 4.1K | 597.7K | 37.67% | ↗ |
| 26 | 2019 | Jon S. Kuwahara Senior Vice President of Finance and Administration | 295.7K | — | — | 95.7K | — | 1.4K | 392.9K | 24.36% | ↗ |
| 27 | 2018 | Gregory J. Flesher Chief Executive Officer | 459.9K | — | 99.3K | 191.3K | 191.2K | 1.4K | 943.1K | 30.81% | ↗ |
| 28 | 2018 | Catherine C. Turkel President | 357.7K | — | 64.7K | 81.3K | 119.0K | 2.9K | 625.5K | 23.33% | ↗ |
| 29 | 2018 | Jon S. Kuwahara Senior Vice President of Finance and Administration | 281.1K | — | 36.4K | 40.6K | 70.1K | 1.4K | 429.6K | 17.93% | ↗ |
| 30 | 2017 | Gregory J. Flesher Chief Executive Officer | 290.0K | 100.0K | — | 575.1K | — | 1.5K | 966.6K | 59.50% | ↗ |
| 31 | 2017 | Jodie P. Morrison Former President and Chief Executive Officer | 218.8K | — | — | 73.4K | — | 622.4K | 914.6K | 8.03% | ↗ |
| 32 | 2017 | John S. McBride Former Chief Operating Officer and Chief Financial Officer | 169.9K | — | — | 73.4K | — | 404.0K | 647.3K | 11.34% | ↗ |
| 33 | 2017 | Catherine C. Turkel President | 205.8K | 80.0K | — | 284.6K | — | 2.5K | 572.9K | 49.68% | ↗ |
| 34 | 2017 | Christine G. Ocampo Former Chief Financial Officer | 60.8K | 80.0K | — | 139.2K | — | 28.2K | 308.2K | 45.16% | ↗ |
| 35 | 2017 | Jon S. Kuwahara Senior Vice President of Finance and Administration | 121.6K | — | — | 136.1K | — | 585.00 | 258.3K | 52.68% | ↗ |
| 36 | 2016 | Jodie P. Morrison Former President and Chief Executive Officer | 525.0K | — | — | — | — | 281.00 | 525.3K | 0.00% | ↗ |
| 37 | 2016 | Lee H. Kalowski Former Chief Financial Officer | 320.0K | — | — | — | — | 114.4K | 434.4K | 0.00% | ↗ |
| 38 | 2016 | John S. McBride Former Chief Operating Officer and Chief Financial Officer | 407.8K | — | — | — | — | 281.00 | 408.1K | 0.00% | ↗ |
| 39 | 2015 | Gerald E. Quirk, Esq. General Counsel; EVP, Business Operations | 218.5K | — | — | 1.92M | 52.2K | 546.00 | 2.20M | 87.65% | ↗ |
| 40 | 2015 | Jodie P. Morrison Former President and Chief Executive Officer | 475.0K | — | — | 1.20M | 166.3K | 335.00 | 1.84M | 65.15% | ↗ |
| 41 | 2015 | Jodie P. Morrison President and Chief Executive Officer | 475.0K | — | — | 1.20M | 166.3K | 335.00 | 1.84M | 65.15% | ↗ |
| 42 | 2015 | John S. McBride Former Chief Operating Officer and Chief Financial Officer | 377.8K | — | — | 393.5K | 124.1K | 281.00 | 895.6K | 43.93% | ↗ |
| 43 | 2015 | Karen J. Ferrante, M.D. Chief Medical Officer | 380.0K | — | — | 393.5K | 93.1K | 335.00 | 866.9K | 45.39% | ↗ |
| 44 | 2015 | Lee H. Kalowski Former Chief Financial Officer | 320.0K | — | — | 393.5K | 46.0K | 30.9K | 790.4K | 49.78% | ↗ |
| 45 | 2014 | Lee H. Kalowski Former Chief Financial Officer | 110.7K | 91.0K | 817.3K | 2.27M | — | 20.00 | 3.29M | 93.87% | ↗ |
| 46 | 2014 | Jodie P. Morrison President and Chief Executive Officer | 373.9K | — | — | 1.93M | 234.6K | 881.00 | 2.54M | 75.99% | ↗ |
| 47 | 2014 | Jodie P. Morrison President and Chief Executive Officer | 373.9K | 234.6K | — | 1.93M | — | 50.00 | 2.54M | 76.01% | ↗ |
| 48 | 2014 | Karen J. Ferrante, M.D. Chief Medical Officer | 249.3K | 50.0K | — | 1.15M | 109.5K | 65.5K | 1.62M | 70.73% | ↗ |
| 49 | 2013 | Jodie P. Morrison President and Chief Executive Officer | 330.1K | 91.9K | — | 547.1K | — | 565.00 | 969.7K | 56.42% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David-Alexandre C. Gros | Chief Executive Officer & Non Independent Director | 1M | — |
| Steven N. Perrin | President, Chief Scientific Officer & Non Independent Director | 784.1K | — |
| Paul Sean Little | Chief Financial Officer | 724.5K | male |
| Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer | 377.1K | male |
| John Herberger | Vice President of Technical Operations | — | male |
| Marina Escudero | Vice President & Head of Clinical Operations | — | female |
| Eliezer Katz | Chief Medical Officer | — | — |
| David Hovland | Chief Regulatory Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ELDN
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
